45 completed, 9 terminated, 9 unknown, 7 recruiting. 74 Phase 2, 21 Phase 1.
Follow Peripheral T-Cell Lymphoma: new trials by email Literature Review of Peripheral T-Cell Lymphoma trials Research Report on Peripheral T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 176 | 2025-08-15 | 2026-07-29 |
| Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma chidamide and golidocitinib - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 45 | 2024-12-30 | 2025-01-03 |
| Golidocitinib Plus CHOP in Newly Diagnosed PTCL Golidocitinib plus CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 68 | 2024-09-01 | 2024-12-18 |
| Linperlisib Combined With Chidamide in Patients With PTCL Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Yanyan Liu | 134 | 2024-05-25 | 2025-12-05 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma Linperlisib in combination with CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 44 | 2023-08-15 | 2026-09-16 |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2022-05-01 | 2022-07-01 |
| AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) AZD4205 - Peripheral T-cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 48 | 2022-03-17 | 2025-07-04 |
| Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL Sintilimab, Chidamide, Azacidine - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Peking University | 30 | 2021-04-15 | 2021-03-09 |
| Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Lenalidomide, Cyclophosphamide, Doxorubicin - Peripheral T-Cell Lymphoma, Lenalidomide | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 289 | 2021-04-01 | 2022-11-07 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL) TQ-B3525 - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 78 | 2020-12-01 | 2020-11-04 |
| Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PD-1 antibody+ HDAC inhibitor - Peripheral T-cell Lymphoma | Phase 2 | Recruiting | Fudan University | 51 | 2020-11-13 | 2026-04-02 |
| A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression brentuximab vedotin, cyclophosphamide, doxorubicin - Peripheral T-cell Lymphoma | Phase 2 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 82 | 2020-11-12 | 2026-08-13 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 56 | 2020-08-18 | 2026-01-05 |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma CHOP, CHOP+X - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 96 | 2020-07-29 | 2023-06-13 |
| Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy Azacitidine, Chidamide - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 28 | 2020-06-20 | 2022-04-20 |
Showing 20 of 74. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (74) · Lymphoma, T-Cell, Cutaneous (26) · Immunoblastic Lymphadenopathy (24) · Lymphoma, Large-Cell, Anaplastic (24) · Lymphoma, Non-Hodgkin (24) · Leukemia, Lymphocytic, Chronic, B-Cell (23) · Lymphoma, Large B-Cell, Diffuse (23) · Lymphoma, Extranodal NK-T-Cell (22) · Lymphoma, Follicular (22) · Lymphoma, Mantle-Cell (22) · Mycosis Fungoides (22) · Sezary Syndrome (22) · Lymphoma, B-Cell, Marginal Zone (21) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (21) · Hodgkin Disease (20)
Hemic and Lymphatic Diseases (74) · Immune System Diseases (74) · Immunoproliferative Disorders (74) · Lymphatic Diseases (74) · Lymphoproliferative Disorders (74) · Neoplasms by Histologic Type (74) · Neoplasms (72) · Lymphoma, T-Cell (68) · Lymphoma (66) · Lymphoma, Non-Hodgkin (50) · Hematologic Diseases (29) · Disease Attributes (27) · Leukemia (27) · Leukemia, Lymphoid (27) · Pathologic Processes (27)
Cyclophosphamide (15) · Prednisone (10) · Whole-Body Irradiation (10) · Mycophenolic Acid (9) · fludarabine phosphate (9) · Peripheral Blood Stem Cell Transplantation (8) · Cyclosporine (7) · Doxorubicin (7) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (7) · Vincristine (7) · Etoposide (6) · Alemtuzumab (5) · Gemcitabine (5) · Lenalidomide (5) · 10-propargyl-10-deazaaminopterin (4)
Fred Hutchinson Cancer Center (9) · Kyowa Kirin Co., Ltd. (3) · Acrotech Biopharma Inc. (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Northwestern University (2) · Peking Union Medical College Hospital (2) · Ruijin Hospital (2) · Sun Yat-sen University (2) · University of Nebraska (2) · AbbVie (prior sponsor, Abbott) (1) · Aileron Therapeutics, Inc. (1) · Akeso (1) · Antengene Corporation (1) · Asana BioSciences (1)
United States (43) · China (18) · Italy (12) · France (7) · United Kingdom (6) · Germany (5) · Japan (4) · Spain (4) · Belgium (3) · Canada (3) · Denmark (3) · Thailand (3) · Israel (2) · Netherlands (2) · Poland (2)
Brenda Sandmaier (3) · Ajay Gopal (2) · David Maloney (2) · Adam Lerner, MD (1) · Adam Petrich, MD (1) · Alain Delmer, MD (1) · Amanda Cashen, MD (1) · Andreas Neubauer, MD (1) · Andreas Viardot, MD (1) · Andrei Shustov, MD (1) · Beata Holkova, MD (1) · Bernard Poiesz, MD (1) · Bertrand Coiffier, MD (1) · Charles Farber, MD (1)
PMID 32499241, PMID 19900571, PMID 21504290, PMID 22271479, PMID 24456586, PMID 25279222, PMID 25404094, PMID 25605368, PMID 25605745, PMID 26213141, PMID 26764356, PMID 26921086, PMID 26965915, PMID 27071522, PMID 27418646, PMID 28420721, PMID 28771889, PMID 30952672, PMID 31917843, PMID 33236943, PMID 34230007, PMID 34670169, PMID 36399518, PMID 36661315, PMID 37319432, PMID 37327113, PMID 39175480, PMID 42018969, PMID 42438166
P30CA015704 (7), P01CA018029 (3), P01CA078902 (2), 2008 (1), 2019 (1), N01CM00039 (1), N01CM62202 (1), P30CA016672 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), U10CA021115 (1)